Bartter syndrome is a rare genetic disorder that causes specific defects in kidney function. Over the past few years, it is observed that different terminologies have been used to describe Bartter syndrome. Some classify Bartter syndrome on the basis of its clinical appearance, whereas others classify it on the basis of its underlying mutated gene. On the basis of the underlying gene mutation, Bartter syndrome can be classified as Bartter syndrome type 1, type 2, type 3, type 4a and 4b and Gitelman syndrome.The Market Research Survey by “Fact.MR, A Market Research and Competitive Intelligence Provider” highlights the key reasons behind the increasing demand for Bartter Syndrome Treatment Market.
Presently, according to the National Organization for Rare Disorders (NORD), Bartter syndrome is classified under a new classification system, which is based upon the specific part of the kidney affected. This includes loop disorders, DCT disorders and combined DCT and loop disorders. Loop disorders include Bartter syndrome type 1 and type 2 and DCT disorders include Gitelman syndrome. Combined DCT and loop disorders include Bartter syndrome type 3, type 4a and 4b.
To Get In-depth Insights Request for Brochure here – https://www.factmr.com/connectus/sample?flag=B&rep_id=2192
The defects caused by Bartter syndrome impair the kidney’s ability to reabsorb salt and imbalance the fluid concentrations of various electrolytes in the body. The electrolytes affected by Bartter syndrome are generally mineral salts such as calcium, potassium, sodium, chloride and magnesium. Bartter syndrome is caused by alteration in one of the several different genes. Most of the subtypes of Bartter syndrome are inherited in an autosomal recessive manner. Bartter syndrome symptoms vary from person-to-person and its severity ranges from mild to severe. Bartter syndrome treatment aims at correcting electrolyte imbalance and includes the use of supplements and medications such as diuretics and non-steroidal anti-inflammatory drugs (NSAIDs).
The diagnosis of Bartter syndrome includes laboratory tests such as blood tests for determining serum electrolyte levels, especially renin and magnesium and aldosterone levels, and urine tests for determining the presence of prostaglandin E2 and urine electrolytes. In addition, molecular genetic testing is also used for the diagnosis of Bartter syndrome. Molecular genetic testing detects the mutations in specific genes, which causes Bartter syndrome. However, molecular genetic testing is only available at specialized laboratories as a diagnostic service.
Request Customized Report as Per Your Requirements – https://www.factmr.com/connectus/sample?flag=RC&rep_id=2192
Bartter syndrome treatment requires lifelong administration of certain supplements and medications. Presently, there is no cure for Bartter syndrome; however, restoring the proper balance of fluids and electrolytes in the body with certain medication can effectively work as Bartter syndrome treatment. For instance, indomethacin is a nonsteroidal anti-inflammatory drug which reduces the prostaglandin levels in the body. This further reduces excess urine production and the need for potassium supplements. Indomethacin is usually an effective and well-tolerated Bartter syndrome treatment. Some patients may require medications such as potassium-sparing diuretics such as spironolactone or amiloride. Growth hormone therapy is also considered as a successful Bartter syndrome treatment.
Strong R&D and increasing awareness in low-middle income countries are further responsible for driving the growth of the global Bartter syndrome treatment market over the forecast period. Generally, Bartter syndrome affects both males and females in equal numbers. According to NORD, Bartter syndrome affects around one in 1,000,000 individuals in the overall population.
Difficulties in diagnostic tests and stringent regulations are expected to hamper the growth of the global Bartter syndrome treatment market.
The report covers exhaustive analysis on
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies Involved
- Value Chain
Enquire Before Buying Here – https://www.factmr.com/connectus/sample?flag=EB&rep_id=2192
- North America (U.S., Canada)
- Latin America (Mexico, Brazil, Argentina, Peru, Chile, Rest of LATAM)
- Europe (Germany, Italy, U.K., Spain, France, Nordic countries, BENELUX, Eastern Europe, Rest of Europe)
- CIS & Russia
- Asia Pacific Excluding Japan (Greater China, India, South Korea, ASEAN Countries, Rest of APEJ)
- Middle East and Africa (GCC Countries, Turkey, Iran, Israel, S. Africa, Rest of MEA)
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
Bartter Syndrome Treatment Market: Segmentation
Tentatively, the global Bartter syndrome treatment market can be segmented on the basis of Bartter syndrome treatment drug type, distribution channel and geography.
Based on Bartter syndrome treatment drug type, the global Bartter syndrome treatment market has been segmented as:
- NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
- RAAS Inhibitors
- Aldosterone Antagonists
- Angiotensin II Receptor Blockers
- Angiotensin-Converting Enzyme (ACE) Inhibitors
Based on distribution channel, the global Bartter syndrome treatment market has been segmented as:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
Explore Fact.MR’s Coverage on the Healthcare Domain:
Digital Therapeutics Market – According to the latest research by Fact.MR, the digital therapeutics market is set to witness exponential growth during 2021-2031. Increasing adoption for digital health to deliver evidence-based therapeutics will witness a promising growth outlook for digital therapeutics in the long run.
Leukocyte Count Testing Market – According to the latest research by Fact.MR, the leukocyte count testing market is set to witness exponential growth with over 7%-8% CAGR during 2021-2031. Increasing bacterial infection with the growing adoption of point of care devices will witness a promising growth outlook for leukocyte count testing in the long run.
Polysaccharide Hemostatic System Market – According to the latest research by Fact.MR, Polysaccharide Hemostatic System market is set to witness a XX% growth during the year 2021-2031.
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
US Sales Office:
11140 Rockville Pike
Rockville, MD 20852
Tel: +1 (628) 251-1583
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates